Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAshmore Group Regulatory News (ASHM)

Share Price Information for Ashmore Group (ASHM)

Share Price is delayed by 15 minutes
Get Live Data
202.60    0.00 (0.00%)
Bid:
202.60
Ask:
203.00
Spread: 0.40 (0.197%)
Market Cap: £1.32b
ASHM Live PriceLast checked at - London Stock Exchange

Intraday Ashmore Group Share Chart

Trading Statement

16 Jan 2018 07:00

RNS Number : 9411B
Ashmore Group PLC
16 January 2018
 

Ashmore Group plc+0700 16 January 2018

SECOND QUARTER ASSETS UNDER MANAGEMENT STATEMENT

Ashmore Group plc ("Ashmore", "the Group"), the specialist Emerging Markets asset manager, announces the following update to its assets under management ("AuM") in respect of the quarter ended 31 December 2017.

Assets under management

Theme

Actual30 September 2017

(US$ billion)

Estimated31 December 2017

(US$ billion)

Movement

(%)

External debt

14.4

15.0

+4%

Local currency

12.7

14.9

+17%

Corporate debt

6.9

7.8

+13%

Blended debt

18.8

18.8

-

Equities

3.5

3.9

+11%

Alternatives

1.6

1.6

-

Multi-asset

1.1

1.2

+9%

Overlay / liquidity

6.0

6.3

+5%

Total

65.0

69.5

+7%

 

Assets under management increased by US$4.5 billion during the period, with net inflows of US$3.6 billion and positive investment performance of US$0.9 billion.

The continued strong net inflows in the quarter are consistent with this stage in the cycle as investors appreciate the high returns available and look to address underweight positions. Gross subscriptions increased from a broad range of clients, including both additional allocations from existing investors and new mandates. Net inflows were particularly strong in the local currency theme as investors are now recognising the significant value available. Net inflows were also delivered in the corporate debt, overlay/liquidity, equities and external debt themes. Net flows were broadly flat in the blended debt, alternatives and multi-asset themes.

Ashmore delivered positive absolute performance in the quarter across both fixed income and equities product ranges while performance was flat in alternatives and overlay/liquidity. Relative performance against both benchmarks and the peer group continues to be very strong.

Mark Coombs, Chief Executive Officer, Ashmore Group plc, commented:

"Emerging Markets assets have delivered strong absolute and relative performance over the past two years leading to higher client flows into the Group's funds. Additionally, competitive currencies have been driving exports thus accelerating economic growth across Emerging Markets. The next phase of the cycle should see institutional flows stimulating domestic demand and so provide for continued attractive returns, particularly from local currency-denominated assets including equities. Our 2018 outlook is for another year of outperformance across the range of Emerging Markets asset classes."

 

Notes

1. For the translation of US dollar-denominated balance sheet items, the GBP:USD exchange rate was 1.3513 at 31 December 2017 (30 June 2017: 1.2946; 31 December 2016: 1.2340). For the translation of US dollar management fees, the average GBP:USD exchange rate achieved for the first half of the financial year was 1.3259 (H1 2016/17: 1.2809).

Ashmore will announce its interim results in respect of the six months ended 31 December 2017 on 8 February 2018.

Ashmore's Legal Entity Identifier (LEI) is 549300U3L59WB4YI2X12.

For further information please contact:

Ashmore Group plcPaul MeasdayInvestor Relations +44 (0)20 3077 6278

FTI ConsultingAndrew Walton +44 (0)20 3727 1514Laura Ewart +44 (0)20 3727 1160

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLLFITLFIELIT
Date   Source Headline
14th Aug 20185:16 pmRNSHolding(s) in Company
13th Jul 20187:00 amRNSTrading Statement
2nd Jul 20188:44 amRNSDirectorate Change
20th Apr 20184:30 pmRNSDirector/PDMR Shareholding
17th Apr 20187:00 amRNSTrading Statement
4th Apr 20184:32 pmRNSDirector/PDMR Shareholding
29th Mar 20184:00 pmRNSDirector/PDMR Shareholding
8th Feb 20187:00 amRNSHalf-year Report
16th Jan 20187:00 amRNSTrading Statement
6th Dec 20171:55 pmRNSDirectorate Change
5th Dec 201711:45 amRNSDirector/PDMR Shareholding
5th Dec 201710:57 amRNSDirector/PDMR Shareholding
20th Oct 20173:08 pmRNSResult of AGM
13th Oct 20174:49 pmRNSDirector/PDMR Shareholding
13th Oct 20177:00 amRNSTrading Statement
19th Sep 20172:11 pmRNSDirector/PDMR Shareholding
19th Sep 20172:07 pmRNSDirector/PDMR Shareholding
7th Sep 20177:00 amRNSFinal Results
14th Jul 20177:00 amRNSTrading Statement
16th Jun 20177:00 amRNSInvestor presentation
21st Apr 20174:30 pmRNSDirector/PDMR Shareholding
18th Apr 20177:00 amRNSTrading Statement
10th Apr 20175:19 pmRNSDirector/PDMR Shareholding
29th Mar 20179:23 amRNSHolding(s) in Company
28th Mar 20174:54 pmRNSDirector/PDMR Shareholding
9th Feb 20177:00 amRNSHalf-year Report
16th Jan 20177:00 amRNSTrading Statement
21st Oct 20163:57 pmRNSResult of AGM
14th Oct 20167:00 amRNSTrading Statement
21st Sep 20164:30 pmRNSDirector/PDMR Shareholding
21st Sep 20164:30 pmRNSDirector/PDMR Shareholding
6th Sep 20167:00 amRNSFinal Results
10th Aug 201610:45 amRNSHolding(s) in Company
14th Jul 20167:00 amRNSTrading Statement
18th May 201610:00 amRNSAppointment of joint corporate broker
20th Apr 20164:28 pmRNSHolding(s) in Company
19th Apr 20167:00 amRNSTrading Statement
15th Apr 20164:39 pmRNSHolding(s) in Company
4th Apr 20168:56 amRNSDirector/PDMR Shareholding
24th Mar 20165:30 pmRNSDirector/PDMR Shareholding
23rd Mar 20168:21 amRNSHolding(s) in Company
11th Feb 20167:00 amRNSHalf Yearly Report
14th Jan 20167:00 amRNSTrading Statement
11th Dec 20155:30 pmRNSDirector/PDMR Shareholding
11th Dec 20155:28 pmRNSDirectorate Change
7th Dec 201510:13 amRNSDirector/PDMR Shareholding
13th Nov 20159:15 amRNSDirector/PDMR Shareholding
28th Oct 201511:56 amRNSForm 8.3 - Al Noor Hospitals Group PLC
28th Oct 201511:52 amRNSForm 8.3 - NMC Health plc
27th Oct 20154:42 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.